Squarepoint’s Aligos Therapeutics ALGS Stock Holding History

Squarepoint’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-30,493	Closed	-$299K	–	4215
2025 Q3	$299K	Buy	30,493 +11,904	+64%	+$109K	﹤0.01%	3674
2025 Q2	$134K	Buy	+18,589	New	+$111K	﹤0.01%	4089

Other funds holding ALGS

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SummitTX Capital Fort Worth, Texas $3.2B AUM 41.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Squarepoint's ALGS Position: Q4 2025 in Review

Squarepoint sold out of Aligos Therapeutics (ALGS) in Q4 2025, closing a stake of 30,493 shares — an estimated $299K sold.

Squarepoint first reported a position in ALGS in Q2 2025 and held it in 2 quarters. The position peaked at $299K in Q3 2025. 40 funds tracked by Wall St. Rank hold ALGS as of Q4 2025.

Squarepoint reported no remaining Aligos Therapeutics position as of Q4 2025 after selling out during the quarter.
Squarepoint sold 30,493 Aligos Therapeutics shares in Q4 2025, an estimated $299K.
Squarepoint first reported a position in Aligos Therapeutics in Q2 2025 and held it in 2 quarters.
Squarepoint's Aligos Therapeutics position peaked at $299K in Q3 2025.
40 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q4 2025.

Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.